

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Menne et al.

Art Unit: 1635

Application No: 10/528,806

Examiner: Richard Schnizer

Confirmation No: 6218

Filed: June 14, 2006

Atty. Docket No: 37998-237159

For: INHIBITION OF PROTEIN KINASE C
ALPHA FOR THE TREATMENT OF
CARDIOVASCULAR DISEASES

Customer No:

26694

26694

PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

References AA, AE, BA, and CA to CJ were cited in the International Search Report for the parent PCT Application. A copy of the search report was submitted with the national stage filing on June 14, 2005.

References, AC-AD and BD-BF were cited in a Office Action during prosecution of the parent German application.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 37998-237159. A duplicate copy of this paper is enclosed.

Dated: April 7, 2006

Respectfully submitted,

By Kavita B. Lepping
Kavita B. Lepping
Registration No.: 54,262
VENABLE LLP
P.O. Box 34385
Washington, DC 20043-9998
(202) 344-4000
(202) 344-8300 (Fax)
Attorney/Agent For Applicant

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known Application Number 10/528,806-Conf. #6218 Filing Date June 14, 2006 First Named Inventor Jan Meene Art Unit Not Yet Assigned Examiner Name Not Yet Assigned Attorney Docket Number 37998-237159		
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number/Kind Code ² (if known)			
	AA*	US-5,674,902 A	10-07-1997	Szallasi Zoltan et al.	
	AB*	US-2005/0066381 A1	03-24-2005	Molkenitin et al.	
	AC*	US-5,936,084	08-10-1999	Jirousek et al.	
	AD*	US-5,344,841	09-06-1994	Jiang et al.	
	AE*	US-6,063,814	05-16-2000	Chang et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	DE-197 40 384 A1	03-11-1999			
	BB	WO-97/07787	03-06-1997			
	BC	WO-2005/027629 A2	03-31-2005			
	BD	DE-39 24 538 A1	01-31-1991			
	BE	DE-696 00 784	04-08-1999			
	BF	DE-39 14764 A1	11-08-1990			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO: Those application(s) which are marked with an angle asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.96(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IPW. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/528,806-Conf. #6218
		Filing Date	June 14, 2006
		First Named Inventor	Jan Meene
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet	2	of	2
		Attorney Docket Number	37996-237159

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	Menne, J. et al., "Protein kinase C alpha deficiency ameliorates the development of diabetic nephropathy in mice with streptozotocin-induced hyperglycemia," <i>Kidney and Blood Pressure Research</i> , Bd. 24, Nr. 4-6, 2001, Seite 231		
	CB	Menne, Jan et al., "Protein kinase C alpha deficiency ameliorates the development of diabetic nephropathy in mice with streptozotocin-induced hyperglycemia," <i>Journal of the American Society of Nephrology</i> , Bd. 12, Nr. Program and Abstract Issue, September 2001 (2001-09), Seite 151A.		
	CC	Meier, Matthias et al., "Knockout of protein kinase C alpha protects against the development of albuminuria but not renal hypertrophy," <i>Diabetes</i> , Bd. 52, Nr. Supplement 1, 2003, Seite A50		
	CD	Kang, Ningling et al., "Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats," <i>Kidney International</i> , Bd. 56, Nr. 5, November 1999		
	CE	Database Biosis 'Online' Biosciences Information Service, "Effect of cyclosporin-A on teh blood-retinal barrier permeability in streptozotocin-induced diabetes," <i>XP002278387</i> , <i>Mediators of Inflammation</i> , Bd. 9, Nr. 5, 2000, Seiten 243-248, ISSN: 0962-9351		
	CF	Database Biosis 'Online' Biosciences Information Service, Philadelphia, PA, June 1998 (1998-06) Koya Daisuke et al., "Protein kinase C activation and the development of diabetic complications," <i>XP002292425</i>		
	CG	Database Biosis 'Online' Biosciences Information Service, Philadelphia, PA, October 23, 2001 (2001-10-23) Venugopal Senthil Kumar et al., "alpha-Tocopherol inhibits hyperglycemia-induced superoxide anion release from human monocytes via inhibition of PKC-alpha," <i>XP008034017</i>		
	CH	Database Medline 'Online' US National Library of Medicine (NLM), Bethesda, MD, September 1997 (1997-09) Hempel A. et al., "High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha," <i>XP002292426</i>		
	CI	Database Medline 'Online' US National Library of Medicine (NLM), Bethesda, MD, June 1996 (1996-06) Busuttil S J et al., "Antisense suppression of protein kinase C alpha and -delta in vascular smooth muscle," <i>XP002292427</i>		
	CJ	Database Biosis 'Online' Biosciences Information Service, Philadelphia, PA, September 2001 (2001-09) Takahashi Tomoya et al., "Cyclosporin A promotes hair epithelial cell proliferation and modulates protein kinase C expression and translocation in hair epithelial cells," <i>XP002292428</i>		

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with initial communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language translation is attached.

DC 2 800500

Examiner Signature	Date Considered
--------------------	-----------------